Evaluation of the clinical pharmacist's effect on achieving treatment goals in patients with hypothyroidism: a randomized controlled trial.

Total drug-related problems (DRPs) in the intervention group significantly decreased between the first and second visits following clinical pharmacist intervention.

• The total number of DRPs in the intervention group decreased from 66 to 24 between the first and second visits (p < 0.001).
• A total of 118 DRPs belonging to both groups were detected across the study.
• DRPs were identified and classified based on Pharmaceutical Care Network Europe (PCNE) v9.1 criteria.
• The study period ran from March 2022 to September 2022 with assessments at first visit and again two months later.

Potential drug-drug interactions (pDDIs) in the intervention group were eliminated entirely following clinical pharmacist intervention.

• Total potential drug-drug interactions decreased from 21 to 0 in the intervention group between the first and second visits (p < 0.001).
• This complete elimination of pDDIs occurred over a two-month intervention period.
• The intervention group consisted of 18 patients attending a university hospital's endocrinology and metabolism outpatient clinic.

Adherence to the timing of levothyroxine (LT4) medication administration significantly increased in the intervention group between visits.

• Adherence to the time of taking medication increased from 55.5% to 94.4% in the intervention group between the first and second visits (p = 0.008).
• Overall adherence levels between the control group and intervention group showed no statistically significant difference at either visit (p > 0.05).
• Adherence was measured using the validated Morisky-Green-Levine (MGL) 4-question scale.

The study enrolled 43 patients with hypothyroidism, with diabetes and hypertension being the most prevalent comorbidities in both groups.

• Participants were randomly assigned to a control group (n = 25) and an intervention group (n = 18).
• Diabetes prevalence was 21.6% in the control group and 20.5% in the intervention group.
• Hypertension prevalence was 16.2% in the control group and 11.7% in the intervention group.
• All patients were assessed during their first visit and again two months later at their second visit.

Drug-related problems and levothyroxine therapy adherence problems were found to occur frequently in patients with hypothyroidism.

• A total of 118 DRPs were detected across both groups during the study.
• The study highlights that LT4 therapy involves lifelong thyroxine replacement therapy and regular monitoring, making adherence particularly important.
• The findings suggest that CP intervention could significantly contribute to improving patients' treatment outcomes by increasing adherence and decreasing DRPs.